Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRC-01 Intratumoral Injection Combined With Radiotherapy in Patients With Locally Advanced Cervical Cancer
NCT05570422Phase 1Recruiting
- Sponsor
- KORTUC Inc.
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of KRC-01 in Cervical Cancer (CC) (4 arms), sponsored by KORTUC Inc. Primary endpoints: Adverse Events at 36 months, Adverse Events of Special Interest at 36 months and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
KRC-01
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05570422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570422.